EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates

Omar Janha iD, Niniola Olaniyan, Go Ka Diam iD, Saumya Sharma, Dario Beraldi iD, Andrew G Jamieson iD, Zbynek Bozdech, Andrew B Tobin iD, Katarzyna Modrzynska iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01561-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Omar Janha und 8 weiteren Autor:innen. Beteiligte Einrichtung: Keltic Pharma Therapeutics Limited, Advanced Research Centre, University of Glasgow, Glasgow, United Kingdom. Hauptthemen laut MEDLINE: RNA Splicing, Antimalarials, Plasmodium falciparum, Protozoan Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Singapore, Wellcome Trust, Gates Family Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emerging resistance to front-line antimalarials means there is an urgent need to discover new drugs with novel mechanisms of action that remain effective across multiple stages of the parasite life cycle. Previously, we reported a malaria parasite protein kinase, Pf CLK3, as a target offering a cure, prophylaxis, and transmission blocking. The homology between Pf CLK3 and human kinases suggested that the mechanism of parasiticidal activity of Pf CLK3 inhibitors is disruption of RNA processing. Here, we use RNA sequencing to reveal that selective Pf CLK3 inhibition extensively affects RNA splicing with 2,039 splice-junctions across 1,125 genes mis-spliced in treated wild-type parasites compared to controls. The function of mis-spliced transcripts showed that the affected genes were involved in numerous essential parasite processes associated with multiple life cycle stages and revealed transcripts and introns particularly susceptible to inhibition. Our study supports the role of Pf CLK3 as an important regulator of spliceosome activity and establishes the distinct mechanism of parasiticidal activity of Pf CLK3 inhibitors from current front-line treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA SplicingAntimalarialsPlasmodium falciparumProtozoan ProteinsProtein Serine-Threonine KinasesProtein Kinase InhibitorsHumansSpliceosomesProtein-Tyrosine Kinases

Stichwörter der Autor:innen

PfCLK3TCMDC-135051drug discoverymalariamechanisms of actionmitogen-activated protein kinasesprotein kinasessplicingtarget validation

Substanzen

AntimalarialsProtozoan ProteinsProtein Serine-Threonine KinasesProtein Kinase InhibitorsClk dual-specificity kinasesProtein-Tyrosine Kinases

Autor:innen und Institutionen

  • Keltic Pharma Therapeutics Limited, Advanced Research Centre, University of Glasgow, Glasgow, United Kingdom.
  • School of Molecular Biosciences, Advanced Research Centre, University of Glasgow, Glasgow, United Kingdom.
  • School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
  • School of infection and Immunity, College of Medical, Veterinary and Life Science, University of Glasgow, Glasgow, United Kingdom.
  • School of Chemistry Advanced Research Centre, University of Glasgow, Glasgow, United Kingdom.

ORCID-Profile: Omar Janha, Go Ka Diam, Dario Beraldi, Andrew G Jamieson, Andrew B Tobin, Katarzyna Modrzynska

Förderung

  • Ministry of Education, Singapore
  • Wellcome Trust
  • Gates Family Foundation
  • Gates Foundation
  • Bill & Melinda Gates Foundation
  • Royal Society

Zitieren

APA

Janha, O., Olaniyan, N., Diam, G. K., Sharma, S., Beraldi, D., Jamieson, A. G., Bozdech, Z., Tobin, A. B., & Modrzynska, K. (2026). Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01561-25

Vancouver

Janha O, Olaniyan N, Diam GK, Sharma S, Beraldi D, Jamieson AG, et al. Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01561-25

BibTeX
@article{Janha2026,
  author = {Janha, Omar and Olaniyan, Niniola and Diam, Go Ka and Sharma, Saumya and Beraldi, Dario and Jamieson, Andrew G and Bozdech, Zbynek and Tobin, Andrew B and Modrzynska, Katarzyna},
  title = {Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01561-25}
}
Kostenlos starten →